Description
DESCRIPTION:
Dr. Brophy examines the mechanisms of action of select antiseizure medications,
with a focus on SV2A selectivity.
LEARNING
OBJECTIVES:
- Understand how the mechanism of action and pharmacokinetic profiles compare
- Learn more about the discovery process of these antiseizure medications
- Understand the differences in affinity for SV2A, lipophilicity, and brain permeability
FACULTY
Gretchen Brophy, PharmD
Professor of Pharmacotherapy & Outcomes Science and Neurosurgery
Virginia Commonwealth University School of Pharmacy
Richmond, Virginia
Contributors
-
Gretchen Brophy, PharmD, BCPS, FCCP, FCCM, FNCS, MCCM
Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FNCS, MCCM
Professor of Pharmacotherapy & Outcomes Sciences and Neurosurgery
Virginia Commonwealth University School of Pharmacy
Medical College of Virginia Campus
Richmond, Virginia
Past President, Neurocritical Care Society
Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FNCS, MCCM is Professor of Pharmacotherapy & Outcomes Sciences and Neurosurgery at Virginia Commonwealth University (VCU) School of Pharmacy, Medical College of Virginia Campus, in Richmond. She is also a Neurocritical Care Clinical Pharmacist at VCU Health and a Past President of the Neurocritical Care Society. Dr. Brophy received her PharmD from the University of Arizona, College of Pharmacy in Tucson and her postgraduate training includes residencies in Critical Care and Pharmacy Practice at the University of Kentucky Medical Center in Lexington. Dr. Brophy’s research interests include neurocritical care pharmacotherapy, traumatic brain injury, brain injury biomarkers, hemostasis, stroke, sedation and status epilepticus. She is an investigator for the National Institutes of Health, U.S. Department of Defense and industry-funded studies. Dr. Brophy is an invited speaker at national and international conferences and has multiple peer-reviewed publications and book chapters in the area of neurocritical care.